Below are the most recent publications written about "Head and Neck Neoplasms" by people in Profiles.
-
McMillan H, Barbon CEA, Cardoso R, Sedory A, Buoy S, Porsche C, Savage K, Mayo L, Hutcheson KA. Manual Therapy for Patients With Radiation-Associated Trismus After Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2022 05 01; 148(5):418-425.
-
Aggarwal P, Hutcheson KA, Yu R, Wang J, Fuller CD, Garden AS, Goepfert RP, Rigert J, Mott FE, Lu C, Lai SY, Gunn GB, Chambers MS, Li G, Wu CC, Hanna EY, Sturgis EM, Shete S. Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Sci Rep. 2022 04 22; 12(1):6662.
-
Tardini E, Zhang X, Canahuate G, Wentzel A, Mohamed ASR, Van Dijk L, Fuller CD, Marai GE. Optimal Treatment Selection in Sequential Systemic and Locoregional Therapy of Oropharyngeal Squamous Carcinomas: Deep Q-Learning With a Patient-Physician Digital Twin Dyad. J Med Internet Res. 2022 04 20; 24(4):e29455.
-
Wang R, Horwich P, Sandulache VC, Hernandez DJ, Hornig J, Graboyes EM, Liou NE, Skoner J, Haskins AD, Ranasinghe V, Day TA, Sturgis EM, Huang AT. Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppression. Head Neck. 2022 Jul; 44(7):1520-1527.
-
Corredor G, Toro P, Koyuncu C, Lu C, Buzzy C, Bera K, Fu P, Mehrad M, Ely KA, Mokhtari M, Yang K, Chute D, Adelstein DJ, Thompson LDR, Bishop JA, Faraji F, Thorstad W, Castro P, Sandulache V, Koyfman SA, Lewis JS, Madabhushi A. An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients With HPV-Associated Oropharyngeal Cancer. J Natl Cancer Inst. 2022 04 11; 114(4):609-617.
-
Duca M, Lim DW, Subbiah V, Takahashi S, Sarantopoulos J, Varga A, D'Alessio JA, Abrams T, Sheng Q, Tan EY, Rosa MS, Gonzalez-Maffe J, Sand-Dejmek J, Fabre C, Martin M. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. Mol Cancer Ther. 2022 Apr 01; 21(4):625-634.
-
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Apr 01; 28(7):1345-1352.
-
Nosé V, Lazar AJ. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Familial Tumor Syndromes. Head Neck Pathol. 2022 Mar; 16(1):143-157.
-
Vyas A, Gomez-Casal R, Cruz-Rangel S, Villanueva H, Sikora AG, Rajagopalan P, Basu D, Pacheco J, Hammond GRV, Kiselyov K, Duvvuri U. Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy. Proc Natl Acad Sci U S A. 2022 03 22; 119(12):e2100670119.
-
Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist. 2022 03 04; 27(2):e194-e198.